Philips has announced its next-generation AI-powered cardiovascular ultrasound platform, designed to revolutionize cardiac ultrasound analysis by enhancing efficiency and accuracy in echocardiography labs. This new platform integrates seamlessly with Philips’ existing EPIQ CVx and Affiniti CVx systems and utilizes FDA-cleared AI applications to alleviate the burden on echocardiography labs, improving workflow efficiency and accuracy in the early detection of heart disease, a condition affecting 64 million people globally.
The platform features innovative AI algorithms, co-developed with Dr. Lang, capable of accurately detecting regional wall motion abnormalities (RWMAs), which are critical indicators of adverse cardiovascular events. These automated AI assessments aim to streamline the workflow for clinicians and will be detailed at the upcoming American Society of Echocardiography (ASE2024) meeting. By integrating AI applications from Philips DiA Imaging Analysis, the platform enhances the quality and consistency of cardiac imaging, allowing clinicians of various experience levels to interpret ultrasound images more efficiently and accurately.
Additionally, Philips has introduced the X11 4t mini ultrasound transducer to extend enhanced care to a broader range of patients, including pediatric patients. David Handler, VP and Business Leader for Global Cardiovascular Ultrasound at Philips, emphasized that the AI-powered echocardiography solutions empower clinicians with advanced diagnostic capabilities, ultimately improving patient care and outcomes in managing coronary and valvular diseases while boosting overall efficiency in cardiac practices.
Click here to read the original news story.